तुलना करने के लिए मीट्रिक्स | 4133 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4133पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 652.8x | 27.7x | −0.4x | |
PEG अनुपात | −6.79 | 0.12 | 0.00 | |
क़ीमत/बुक | 1.0x | 2.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 3.6x | 4.8x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 29.0% | 55.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 13.5% | 8.3% | अनलॉक करें |
Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company’s products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, Nano, DNAxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company provides integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production and scale up; assay development services; circulating tumor cell and DNA; germline genetic DNA; and FFPE tumor tissue DNA services. It serves academic, research institutions, and pharmaceutical factories. Abnova (Taiwan) Corporation was founded in 2002 and is headquartered in Taipei, Taiwan.